MedinCell S.A (MDCLF PINK) stock market data APIs
$7.0191
0(0%)
as of November 5, 2025
Try our APIs with
free plan!
MedinCell S.A Financial Data Overview
Price chart is built with
Anychart
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Prev. Close
7.0191
Open
7.0191
High
7.0191
Low
7.0191
52 wk Range
6.9757-6.976
Market Cap
1 350 M
Shares Outstanding
33 099 K
Revenue
27 727 K
EPS
-0.2722
Beta
1.029
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 27 727 K
- EBITDA: -10 071 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
Medincell: UZEDY® Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025
MONTPELLIER, France, November 05, 2025--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About Olanzapine Long-Actin...
European Growth Stocks With Up To 33% Insider Ownership
As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing 1.68% and major indices across Germany, Italy, France, and the UK showing positive momentum, investors are in...
Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar ...
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Teva Pharmaceutical Industries Ltd FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
